Background. Although statins, angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) are generally well tolerated, the impact of these therapies individually or in combination on the change in neurocognitive function in persons with human immunodeficiency virus infection is unknown.
reports described statin-associated worsening cognitive function [11] [12] [13] [14] [15] , which prompted a Food and Drug Administration warning for statins that included a risk of adverse neurocognitive events [16] . However, numerous larger observational studies and meta-analyses, including a Cochrane review, have since found no consistent association of statins with neurocognitive decline, and some have suggested a beneficial effect of statins on cognition [17] [18] [19] [20] [21] [22] [23] [24] . Little is known about the effects of statins on neurocognitive function in persons with HIV; in a subset of statin users from the CHARTER HIV study (n = 63), statins were not associated with improved neuropsychological performance [25] .
Renin angiotensin blockade with angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) are effective in lowering albuminuria, in addition to the expected blood pressure lowering effects. In an analysis of 2 large clinical trials, telmisartan, an ARB with anti-inflammatory properties, was associated with significantly reduced odds of neurocognitive decline among subjects with baseline macroalbuminuria [26] .
Although statins and ACEI/ARB are generally safe, well tolerated, and often coprescribed, the impact of these therapies individually, or in combination, on the change in neurocognitive function of HIV-infected persons is unknown. The ACTG ALLRT study provides an ideal cohort to evaluate the effects of statin therapy and/or ACEI/ARB treatment on neurocognitive function over time, in HIV-infected persons who recently started ART. Using a novel method of marginal structural modeling, the impact of these therapies can be estimated from the observational ACTG ALLRT cohort by mimicking a randomized clinical trial.
METHODS
The ACTG ALLRT cohort was a longitudinal cohort study of HIVinfected participants who received randomly assigned ART as part of prospective clinical trials of ART treatment within the ACTG network [27] . Between 2000 and 2007, a total of 5972 participants were enrolled; follow-up ended in 2013. For this analysis, baseline was defined as the time of the first neurologic assessment after enrollment in ALLRT, after ART initiation. Participants included in the current analysis were not taking a statin or an ACEI/ARB within 30 days of the first neurologic assessment (baseline visit), had neurologic function testing available at least once within 30 months after baseline, and had no known neurocognitive dysfunction, current/prior central nervous system opportunistic infections, psychotic disease, active major depressive disorder, and/ or use of antipsychotic medication at or before baseline.
Outcomes
Neurologic function was determined by the Hopkins Verbal Learning Test-Revised (HVLT-R) and the average z scores of 3 combined tests of neurocognitive performance (NPZ-3): Trailmaking A and B tests (TrA, TrB) and the Wechsler Adult Intelligence Scale-Revised digit symbol test (DST) every 48 weeks. Raw scores on HVLT-R and NPZ-3 components were standardized and adjusted for demographic factors (sex, age, race, and educational status) using normative data. Standardized t scores were converted to z scores for the primary outcome [28] . HVLT-R was introduced in the ALLRT study in 2007 [29] . For all standardized scores, positive scores indicate better neurologic function, and negative scores indicate worse neurologic function.
Statins were categorized as (1) lipophilic (atorvastatin, simvastatin, lovastatin, fluvastatin, cerivastatin, and pitavastatin) or (2) hydrophilic (pravastatin and rosuvastatin). Urine samples (random spot) were collected every 48 weeks; the uPCR was calculated (<0.2 is equivalent to 0.2 g of protein per day and considered normal). Estimated glomerular filtration rate was calculated using the Chronic Kidney Disease Epidemiology Collaboration equation.
Statistical Analyses
Time-varying confounders may predict statin and/or ACEI/ ARB use and may also be associated with cognitive function, leading to time-dependent confounding by indication. This analysis used marginal structural models to estimate the causal effect of statin and/or ACEI/ARB therapy within year 1 (ie, early effects of therapy) and during each subsequent year of therapy (ie, prolonged effects of therapy) on neurocognitive outcomes. As illustrated in Figure 1 , we expect neurocognitive function to follow a certain trajectory (β3) without treatment. We hypothesized that the trajectory of neurocognitive function in the first year of statin or ACEI/ARB therapy reflects the baseline slope in addition to the drug effect (β1 + β3), but this trajectory may differ from the longer-term effect after year 1 (β2 + β3), in regard to adverse effects and potential mechanisms.
In observational studies, therapy is initiated due to underlying risk factors. The control population is thus different than Figure 1 . This model assumes the rate of neurocognitive change is the same (β 3 ) until statin or ACEI/ARB therapy is initiated, after which we hypothesize that the rate of change in year 1 of therapy (β 1 + β 3 ) may differ from the effect for each subsequent year (β 2 + β 3 ). Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker. the treatment population. Marginal structural models attempt to mimic a randomized controlled trial by weighting patients to account for factors that may have influenced the initial treatment decision (to start a statin or ACEI/ARB). We used stabilized inverse probability of treatment weights to adjust for measured time-dependent confounders and stabilized inverse probability of censoring weights to adjust for potential selection bias due to censoring [30] . The final weighted general estimating equation (GEE) model used an exchangeable working correlation structure.
The following covariates were included as confounders potentially associated with statin initiation and neurologic outcomes: baseline age (<40, 40-60, or >60 years), sex, white race, Spanish-speaking status, and education level. Participants who went 30 months without a neurologic examination or discontinued ALLRT for reasons other than completion of protocol, death, or site closure were censored. Covariates that were considered confounders potentially associated with censoring and neurologic outcomes included baseline age; sex, white race, Spanish-speaking status, current or prior intravenous drug use at baseline, and time-updated HIV-1 RNA level.
NPZ-3 (primary outcome) and individual components of NPZ-3 and HVLT-R (secondary) outcomes were examined separately. Sensitivity analyses were performed to investigate the effect of statins, censoring at ACEI/ARB initiation, and, for ACEI/ARB therapy, censoring at statin initiation. Exploratory analyses assessed factors associated with neurologic scores after statin initiation and compared hydrophilic versus lipophilic effects using unweighted GEE models, starting follow-up at statin initiation. The third exploratory analysis assessed the effect of ACEI/ARB initiation on uPCR using a piece-wise unweighted GEE model with a knot at the time of treatment initiation. This analysis included all available outcomes for the subset of participants starting ACEI/ARB therapy.
All analyses considered initiation of statin or ACEI/ARB treatment as intention to treat. Differences were considered statistically significant at P <.05; no adjustment was made for multiple comparisons. Analyses were performed using SAS software, version 9.4 (SAS Institute).
RESULTS
Of 5972 ALLRT participants, 3949 met inclusion criteria. Of these participants, 611 (15.5%) started therapy with a statin, 420 (10.6%) with an ACEI/ARB, and 182 (4.6%) with both during the follow-up period (Figure 2 ). At baseline, 53% of participants were <40 years old, and a majority were male (82%), white (56%), and nonsmokers (62%), with CD4 + T-cell counts >200/ µL (79%) and an HIV-1 RNA levels <400 copies/mL (73%), Table 2 . A median of 133 weeks (IQR, 55-245 weeks) lapsed between the first NPZ-3 assessment and statin initiation, and a median of 180 weeks (76-321 weeks) between the first NPZ-3 assessment and ACEI/ARB initiation.
Statin Effects
In the adjusted statin model, neither the first nor subsequent years of statins had a statistically significant impact on the composite NPZ-3 scores (Table 3 and Figure 3 ); similar effects were seen in sensitivity models, which censored at ACEI/ARB initiation (Table 3) . On individual NPZ-3 components (secondary outcomes), the first year of statin therapy was associated with a trend toward improved TrA score (estimate, 0.088; 95% confidence interval [CI], −.010 to .187; P = .08), and subsequent years of statin therapy were associated with small but significantly lower TrA scores (−0.033; −.058 to −.009; P = .007). No significant effects were seen with TrB, DST (Figure 3 ), or HVLT-R (Table 4) scores. When the effect of statin initiation was limited to participants (17%) with baseline NPZ-3 scores less than −1, there was no significant effect on NPZ-3 scores in year 1 (NPZ-3 change, 0.031; 95% CI, −.155 to .216; P = .75). In contrast, a significant negative effect was seen with subsequent years of statin therapy (−0.059; 95% CI, −.11 to −.004; P = .04). As shown in Table 5 , these changes were driven by a negative effect on TrA score (−0.080; 95% CI, −.134 to −.027; P = .003).
Exploratory multivariable analyses identified covariates associated with neurocognitive scores after statin initiation. Greater time in the study (and hence, greater time receiving ART) was associated with improved NPZ-3 scores; older age at statin initiation and suppressed HIV-1 RNA (<400 copies/mL) at the time of statin initiation were associated with lower NPZ-3 scores. In contrast, HVLT-R scores were higher among participants with lower CD4 + T-cell counts at statin initiation and with longer duration of statin therapy. Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker. a Less than 1% of patients were taking lovastatin, fluvastatin, or cervistatin.
b Includes combination tablets with hydrochlorothiazide.
c Less than 1% of patients were taking irbesartan, telmisartan, olmesartan, or cadesartan. 
Angiotensin-Converting Enzyme Inhibitor/Angiotensin Receptor Blocker Effects
In the adjusted ACEI/ARB model, the first year of therapy was associated with a trend toward poorer performance on NPZ-3 scores (−0.068; 95% CI, −.14 to .008; P = .08). The effect was more pronounced in sensitivity analyses that censored participants at the time of statin initiation (−0.111; 95% CI, −.211 to −.012; P = .03; Table 3 ). Significantly lower performance on the DST was observed during year 1 of ACEI/ARB therapy (−0.117; 95% CI, −.217 to .016; P = .02), with minimal effect in each subsequent year (0.00; −.029 to .032, P = .94). There was no significant effect of ACEI/ARB on the other NPZ-3 components (Figure 3) or the HVLT-R score (Table 4) .
When the effect of ACEI/ARB initiation was limited to participants (17%) with NPZ-3 scores less than −1 at baseline, there was no significant effect on NPZ-3 scores in year 1 (NPZ-3 change, −0.093; 95% CI, −.197 to .143; P = .33), but there was a trend toward significant reduction in subsequent years of ACEI/ARB therapy (estimate, −0.057; −.115 to −.001; P = .053). Similar to the statin effect, these changes were driven by a negative effect on TrA score (Table 5) .
In exploratory analyses of the subset of participants starting ACEI/ARB therapy, the rate of change in uPCR before ACEI/ ARB initiation (−0.014; 95% CI, −.034 to .005]) did not significantly differ from the rate of change after initiation (−0.012; −.043 to .019); P = .85). The difference remained nonsignificant when analysis was restricted to those with a uPCR >0.2 (−0.036; 95% CI, −.136 to .064; P = .48).
DISCUSSION
In this cohort of ART-treated HIV-infected persons, the addition of statin or ACEI/ARB therapy had no negative effect on neurocognitive function, as shown by the standardized and validated NPZ-3 score, but modest declines were seen on individual components of the NPZ-3 or HVLT-R with both statins and ACEI/ARB. Among HIV-infected participants, heightened inflammation and immune activation, endothelial dysfunction, and atherosclerotic burden may contribute to NCI [31, 32] . Thus, with the known effects of statins on inflammation, endothelial function, and plaque burden, we had expected to see improved NCI with statin therapy, but we did not.
Overall, we failed to identify a statin effect on our primary outcome of global neurocognitive function (NPZ-3 scores), or secondary outcomes of TrB (executive function), DST (speed of processing), or HVLT-R (verbal learning and memory). In contrast, we found a modest net negative effect of statins on TrA, a measure of processing speed and attention, after 4 years of therapy. In exploratory analyses, we also found a negative impact of statin therapy on the primary outcome of global neurocognitive function among participants with baseline impairment, driven primarily by effects on the TrA component, although this was a small percentage of our overall population. Additionally, we found a potentially detrimental effect of lipophilic compared to hydrophilic statins on HVLT-R. The effect of statin type may be the result of unmeasured bias in prescribing, greater central nervous system penetration, or the more potent LDL-lowering effect of lipophilic statins. Theoretically, reduced cholesterol synthesis could impair neurogenesis or lead to neuronal cell death, although the clinical relevance and link to therapeutic statins has not been established [33, 34] . Participants with ACEI/ARB receipt experienced a small decline in NPZ-3 at 1 year, with no additional effect in subsequent years, suggesting limited detrimental effect of ACEI/ARB on neurocognitive performance. Similar to the statin findings, we also found a negative impact of ACEI/ARB therapy on the secondary outcome of TrA among participants with baseline impairment (NPZ-3 score less than −1), and a trend toward a negative effect on the composite NPZ-3 after the first year of therapy. It has been hypothesized that reactive oxygen species (ROS) contribute to non-AIDS comorbid conditions and that reduction in ROS production may reduce the progression of these conditions; indeed, the protective effects of ACEI/ARB therapy seems to be strongly related to their ROS-lowering effects [35, 36] . For example, ACEI/ARB use has been associated with reduced cardiovascular and all-cause mortality rates in patients with diabetes mellitus and in individuals with or at high risk for cardiovascular disease [37] . Moreover, it has been recently shown that ACEI/ARB exposure is associated with a 45% decrease in all-cause mortality rate in HIV-infected ART-suppressed adults (C. W. Wester, C. A. Jenkins, J. R. Koethe, A. Freeman, R. Kalayjian, A. Mendes, A. G. Abraham, J. E. Lake, K. Erlandson, H. Crane, T. R. Sterling, R. D. Moore, and B. E. Shepherd, unpublished data). Thus, the benefits of ACEI/ARB are likely to be mediated at least in part by their robust anti-inflammatory and antioxidant effects, which we expected would have manifest as improved neurocognitive function, but did not.
Albuminuria and proteinuria serve as markers of kidney disease and have been linked to cardiovascular disease, chronic kidney disease, NCI, and increased mortality in HIV-infected adults [38, 39] . Kalayjian et al [9] found a significant association between urinary protein excretion (uPCR) and NCI only in patients having significant proteinuria (uPCR >200 mg/g). We expected that ACEI/ARB initiation would improve neurocognitive function, mediated through a reduction in proteinuria. However, we failed to identify a reduction in proteinuria or improvement in neurocognitive testing after ACEI/ARB initiation. Notably, 53% of the participants were <40 years of age, and only 14% had a uPCR >0.2.
Our findings prompt further investigations into the long-term cognitive effects of statins and ACEI/ARB in HIV infection, particularly among adults with existing mild NCI. The study has several notable limitations. First, our significant findings may be attributable to chance, because a large number of statistical tests were performed. Second, marginal structural models are highly dependent on the included covariates. Inclusion of additional confounding variables might have altered our findings in either direction. Although we attempted to control for We censored participants at the time of death, thus our findings may represent a survivorship bias. In addition, the results of the exploratory analysis may have been influenced by other factors. For example, the association between improved scores over time among participants with either higher viral load or lower CD4 + T-cell count at the time of statin initiation is probably measuring the impact of effective ART on neurocognitive function rather than a statin effect. Those who were the sickest at the time of statin initiation had greater improvements in neurocognitive function than those who were already successfully maintained with ART. In summary, although we detected modest negative neurocognitive effects for statins and ACEI/ARB therapy on single cognitive domains, these effects are overwhelmed by lack of effect on our primary outcome, the summary NPZ-3 score, and by the well-established cardiovascular benefits of statins and ACEI/ARB therapy. Consistent with findings in the general literature, our study did not find consistent evidence that statins or ACEI/ARB have an effect on global neurocognitive function. Future studies should further investigate the long-term effects of these therapies, particularly among HIV-infected persons with greater cognitive impairment and longer time receiving ART. 
